Derek J. Smith

This study reports neutralization titers from 355 human sera against 148 influenza strains, showing reduced neutralization of new H3N2 and H1N1 variants.

This paper introduces a high-throughput pipeline for selective mutational scanning in influenza viruses, enabling rapid assessment of variant fitness and escape potential.

This study characterizes the antigenic properties of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models and finds they are antigenically divergent from existing variants with lower homologous serum titers.

This study predicts antigenic evolution in seasonal influenza viruses by analyzing phylogenetic convergence of HA substitutions near the receptor binding site.

Sequencing-based neutralization of 91 H3N2 and H1N1 hemagglutinins against 302 human sera (27,409 titers) shows reduced titers to H3N2 subclade K and H1N1 D.3.1.1.

The paper creates a high-resolution antigenic map of A(H5) HA and uses it to design vaccine antigens that confer broad immunity against diverse A(H5) viruses.

The paper quantifies neutralizing antibody responses to influenza strains using sera collected in 2024-2025 to inform vaccine-strain selection for 2025.

This study compares neutralizing antibody titers in human and hamster sera against SARS-CoV-2 variants using a live-virus neutralization assay, finding hamster sera show higher reactivity.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

The paper compares SARS-CoV-2 antigenicity across assays and in human and animal model sera, finding similar immunodominance patterns and antigenic maps but differences in titer magnitude and assay-specific fold change.